Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis - 10/06/22
Highlights |
• | The appropriate treatment for large or multinodular HCC (beyond up-to-seven criteria) remains to be further considered. |
• | DEB-TACE using callispheres microspheres disclosed better treatment response, improved survival and lower occurrence rate of AEs than cTACE as the initial treatment for those patients. |
• | Among HCC patients beyond up-to-seven criteria, DEB-TACE treatment was identified as a positive factor for better PFS and OS. |
• | CalliSpheres DEB-TACE might be an alternative treatment for patients with HCC beyond up-to-seven criteria. |
Abstract |
Purpose |
To evaluate clinical outcomes of drug-eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres microspheres and conventional TACE (cTACE) as the initial treatment in patients with unresectable hepatocellular carcinoma (HCC) beyond up-to-seven criteria.
Methods |
The study retrospectively assessed the medical records of HCC patients beyond up-to-seven criteria who received the initial treatment of DEB-TACE or cTACE from June 2016 to December 2019 in our institution. To reduce the patient selection bias, propensity score matching (PSM) analysis was used. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and adverse events (AEs) were compared between the two groups. In addition, prognostic factors affecting PFS and OS were analyzed by univariate and multivariate methods.
Results |
A total of 312 eligible HCC patients were included in the study, including 140 patients in the DEB-TACE group and 172 patients in the cTACE group. 110 patients were chosen in each group after PSM analysis and there were no significant differences in baseline characteristics (P > 0.05). Before PSM analysis, DEB-TACE had better ORR and DCR compared to cTACE group (P < 0.05). After PSM analysis, the ORR for DEB-TACE group was still higher than that for cTACE group, while no significant difference in the DCR between the two groups. In addition, DEB-TACE group had better survival benefits than cTACE group before PSM analysis (mPFS: 11.5 months vs 9.0 months, P < 0.001; mOS: 24.0 months vs 19.2 months, P = 0.045). Similarly, after PSM analysis, the median PFS and OS in the DEB-TACE group were still higher than that in the cTACE group (mPFS: 11.1 months vs 9.0 months, P = 0.015; mOS: 25.0 months vs 19.0 months, P = 0.030). Further, the univariate and multivariate analysis indicated that DEB-TACE treatment was a positive prognostic factor for PFS and OS.
Conclusion |
DEB-TACE with CalliSpheres microspheres might be an effective and safe treatment for patients with unresectable HCC beyond up-to-seven criteria.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Hepatocellular carcinoma, Up-to-seven criteria, Transarterial chemoembolization, Callispheres drug-eluting beads, Propensity score matching
Mappa
Vol 46 - N° 5
Articolo 101893- Maggio 2022 Ritorno al numero
Articolo precedente
- Detection of occult hepatitis B virus infection among subjects with isolated hepatitis B core antibodies: Results from a 3-year survey in an Italian tertiary-care hospital
- Flora De Conto, Mirko Buttrini, Maria Loretana Dell'Anna, Clara Maccari, Giulia Montanari, Maria Cristina Arcangeletti, Monica Martinelli, Carlo Chezzi, Adriana Calderaro
- Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with COVID-19
- Simona Tripon, Pascal Bilbault, Thibaut Fabacher, Nicolas Lefebvre, Sylvain Lescuyer, Emmanuel Andres, Elise Schmitt, Sabrina Garnier-KepKA, Pierrick Le Borgne, Joris Muller, Hamid Merdji, Frédéric Chaffraix, Didier Mutter, Thomas F Baumert, Ferhat Meziani, Michel Doffoel
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?